Entyvio (Vedolizumab) 300mg Injection

$9,795.00

Ulcerative Colitis
Initial Dose
– 300 mg IV at 0, 2, and 6 weeks
Maintenance Dose
– 300 mg IV every 8 weeks thereafter
– Discontinue therapy in patients who show no evidence of therapeutic benefit by week 14
Crohn Disease
Initial Dose
– 300 mg IV at 0, 2, and 6 weeks
Maintenance Dose
– 300 mg IV every 8 weeks thereafter
– Discontinue therapy in patients who show no evidence of therapeutic benefit by week 14
Find a Physician:
Manufacturer: Takeda 
NDC: 00078-0569-12 Category:

1 Vial = 1 Unit

Description

IV Administration
– Infuse over 30 minutes
– Do not administer by IV push or bolus
– Following infusion, flush with 30 mL of sterile 0.9% sodium chloride injection
– Observe patients during infusion (until complete) and monitor for hypersensitivity reactions; discontinue if a reaction occurs.
 
Storage of Intact Vials
– Refrigerate unopened vials at 2°C to 8°C (36ºF to 46ºF)
– Retain in original package to protect from light
 
Monitoring
– Observe patients during infusion (until complete) and monitor for hypersensitivity reactions
– LFTs
– Tuberculosis screening according to local practice
– Signs/symptoms of infection
– Any new onset or worsening of neurological signs and symptoms